gpt-dict.com

Niacin for Cardiovascular Disease

Verdict: Does not prevent cardiovascular events

Despite improving cholesterol numbers, niacin does not lower the risk of heart attack, stroke, or cardiovascular death, and at high doses it adds serious harms. For cardiovascular prevention it does not work.

D 🔴 D Counter-Evidence Counter-Evidence

🔬Why this grade7-layer evidence engine

This claim earns a counter-evidence grade because the strongest modern trials directly tested niacin and found no cardiovascular benefit. AIM-HIGH (PMID 22085343, n=3,414) and HPS2-THRIVE (PMID 25014686, n=25,673) both added high-dose niacin to statin therapy: event rates were essentially identical to placebo (HR 1.02, 95% CI 0.87-1.21; rate ratio 0.96, 95% CI 0.90-1.03), and AIM-HIGH was halted early for futility. Two meta-analyses agree, with no effect on cardiovascular or coronary mortality (PMID 30977858, RR 0.98 and 0.90; PMID 27793642).

Crucially, niacin's well-documented improvements in HDL and triglycerides did not translate into fewer events, the central lesson here. The apparent benefit seen in older meta-analyses came almost entirely from pre-statin-era trials and disappeared in contemporary, statin-treated patients.

High-dose niacin also carries net harm: the HPS2-THRIVE safety analysis (PMID 31447131) found significantly more new-onset diabetes (HR 1.32), serious bleeding (HR 1.38), and serious infection (HR 1.22). Reflecting this, the FDA withdrew the niacin-plus-statin combination indications in 2016, and Mayo Clinic, Cleveland Clinic, Harvard Health, and specialty bodies all advise against niacin for cardiovascular event reduction.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.34
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
D · Counter-Evidence
Confidence
88%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.15
L1 ExamineGlobal benchmark
0.30
L11 AI re-checkIndependent read
0.30
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
Against Mixed Supports
▸View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.345
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高階證據未達主導 (0 positive vs 1 negative)，由 raw_score 決定
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy (AIM-HIGH)
PMID: 22085343 2011 RCT (double-blind) n = 3,414
Finding: Primary endpoint occurred in 16.4% of niacin group vs 16.2% of placebo group; no incremental clinical benefit from adding niacin to statin therapy despite significant improvements in HDL and triglycerides. Trial stopped early for futility plus an unexpected higher rate of ischemic stroke in the niacin arm.
🟢 High quality Government Effect size: HR 1.02, 95% CI 0.87-1.21, p=0.79
View on PubMed
Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients (HPS2-THRIVE)
PMID: 25014686 2014 RCT (double-blind) n = 25,673
Finding: Primary endpoint occurred in 13.2% of niacin-laropiprant group vs 13.7% of placebo group — no significant reduction in major vascular events. Niacin significantly increased serious adverse events including new-onset diabetes, bleeding, and infection.
🟢 High quality Government Effect size: Rate ratio 0.96, 95% CI 0.90-1.03 (NS)
View on PubMed
Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the HPS2-THRIVE Trial
PMID: 31447131 2019 隨機對照試驗 n = 25,673
Finding: Niacin-laropiprant produced previously unrecognized serious harms with no cardiovascular benefit: new-onset diabetes HR 1.32 (95% CI 1.16-1.51), serious bleeding HR 1.38 (95% CI 1.17-1.63), serious infection HR 1.22 (95% CI 1.11-1.34), disturbance of diabetes control HR 1.56 (95% CI 1.35-1.80).
🟢 High quality Government Effect size: Diabetes HR 1.32; bleeding HR 1.38; infection HR 1.22; all significant excess harm
View on PubMed
Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
PMID: 30977858 2019 統合分析 n = 35,760
Finding: No association of niacin with CVD mortality (RR 0.98, 95% CI 0.90-1.07) or CHD mortality (RR 0.90, 95% CI 0.76-1.06). Apparent benefit on ACS/stroke/revascularization was confined to the no-statin (older 1970s-80s) subgroup; metaregression showed effects moved toward the null after AIM-HIGH and HPS2-THRIVE. Limited evidence for current use as add-on to statins.
🟢 High quality Academic Effect size: CVD mortality RR 0.98 (NS); CHD mortality RR 0.90 (NS)
View on PubMed
Role of Niacin in Current Clinical Practice: A Systematic Review
PMID: 27793642 2017 統合分析 n = 35,206
Finding: Despite raising HDL by ~21.4%, niacin showed no difference in all-cause mortality and only non-significant trends in cardiovascular outcomes. Authors concluded niacin therapy does not meaningfully reduce mortality or recurrent cardiovascular events.
Effect size: All-cause mortality: no significant difference
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
the totality of the scientific evidence no longer supports the conclusion that a drug-induced reduction in triglyceride levels and/or increase in HDL-cholesterol levels in statin-treated patients results in a reduction in the risk of cardiovascular events source↗
L4b EU EFSA
Neutral
L4c UK NHS
Cautious
Taking high doses of nicotinic acid supplements can cause skin flushes. Taking high doses for a long time could lead to liver damage. ... Taking 17mg or less of nicotinic acid supplements a day, or 500mg or less of nicotinamide supplements a day, is unlikely to cause any harm. source↗
L4d TW TFDA / 衛福部
Neutral
菸鹼酸（包括菸鹼醯胺）屬第（八）類營養添加劑；用於錠狀、膠囊狀食品，每日食用限量以菸鹼素當量（N.E.）計不得超過 100 毫克。 source↗
L4e WHO
Neutral
Pellagra is treated with at least 300 mg of nicotinamide in oral divided doses daily for 3-4 weeks. Nicotinamide is recommended in preference to nicotinic acid (niacin) because it does not cause the flushing reaction. source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Against
Research suggests that niacin therapy isn't linked to lower rates of death, heart attack or stroke. Newer studies indicate that niacin provides little additional benefit when compared with statins alone. source↗
L5c Cleveland Clinic
Against
L5d Harvard Health
Against
L5e Specialty Society (condition-mapped)
Against
✓PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-cardiovascular-disease-INT-niacin-001 繁體中文版 →